52.87 May 1, 4:00PM EDT|Pre-Market
:
53.82 
0.91 (1.72%) 7:26AM EDT - Nasdaq Real Time Price
| Prev Close: | 52.87 |
|---|
| Open: | N/A |
|---|
| Bid: | 53.91 x 1000 |
|---|
| Ask: | 53.94 x 2200 |
|---|
| 1y Target Est: | 68.40 |
|---|
| Beta: | 1.06 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 33.03 - 54.98 |
|---|
| Volume: | 28,500 |
|---|
| Avg Vol (3m): | 2,989,330 |
|---|
| Market Cap: | 139.93B |
|---|
| P/E (ttm): | 21.84 |
|---|
| EPS (ttm): | 2.42 |
|---|
| Div & Yield: | 1.69 (3.20%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Sanofi: Q1 2013 business EPS(1) impacted by exclusivity losses in prior yearPR Newswire(Thu 7:00AM EDT)
- Sanofi Q1 2013 - Interview with CFO Jérôme ContamineBusiness Wire(Thu 1:45AM EDT)
- 3 Investment Ideas for Biotech Investorsat Motley Fool(Wed, May 1)
- Earnings Beat at HospiraZacks(Wed, May 1)
- Sanofi Pasteur Scholarships awarded to four HEC Montréal studentsCNW Group(Wed, May 1)
- 3 Pharmaceutical Companies Awaiting FDA Approval, Part IIat Seeking Alpha(Tue, Apr 30)
- No News Becoming Bad News For Lexicon Pharmaceuticalsat Seeking Alpha(Tue, Apr 30)
- Opportunities Abound for M&A in the Biotech and Pharmaceutical Sectors Given the Need for Major Pharma Companies to Replace Lost Revenues for Drugs That Lost Patent ProtectionWall Street Transcript(Tue, Apr 30)
- NextBio Announces Translational Medicine Partnership with SanofiPR Newswire(Tue, Apr 30)
- 3 Biotech Companies Ripe for a Takeoverat Motley Fool(Tue, Apr 30)
- Wall Street Gets It Backward On Amgen Cholesterol Drugat Forbes(Mon, Apr 29)
- 5 Drugs Stocks Nudging The Industry Higherat TheStreet(Mon, Apr 29)
- Biogen Stock Hits High On Strong Tecfidera Reportat Investor's Business Daily(Mon, Apr 29)
- Italy leads Europe stocks gains; ECB optimismat MarketWatch(Mon, Apr 29)
- BioMarin Widens Loss, Maintains ViewZacks(Mon, Apr 29)
Key Statistics
| Forward P/E (1 yr): | 12.18 |
|---|
| P/S (ttm): | 3.01 |
|---|
| Ex-Dividend Date: | 07-May-12 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.79 |
|---|
| Quarterly EPS Est
(Mar-13)
: | N/A |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | 2.32 |
|---|
Business Summary
Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments.
View More